Miliary Tuberculosis
Overview
Miliary tuberculosis (TB) is a rare, disseminated form of Mycobacterium tuberculosis infection in which millions of tiny bacilli spread through the bloodstream and implant in multiple organs. The name “miliary” comes from the grain‑like (millet‑seed) appearance of the lesions seen on chest X‑ray or CT scans.
Who it affects: While anyone infected with TB can develop the miliary form, it is most common in:
- Infants and young children
- Elderly adults (especially >65 years)
- People with weakened immune systems: HIV/AIDS, organ‑transplant recipients, patients on high‑dose steroids or biologic agents
- Individuals with malnutrition, diabetes, chronic kidney disease, or silicosis
Prevalence: Miliary TB accounts for 1–2 % of all TB cases worldwide, but the proportion rises to 5–10 % among immunocompromised patients.[1] The World Health Organization (WHO) estimates ~10 million new TB cases each year; therefore, roughly 100 000–200 000 people develop the miliary form annually.[2]
Symptoms
Because the infection spreads to many organs, symptoms can be vague and vary widely. Commonly reported features include:
Constitutional
- Fever – typically low‑grade, intermittent, and may become night sweats.
- Weight loss – often >10 % of body weight over weeks.
- Fatigue/weakness – generalized lack of energy.
Respiratory
- Dry cough or mild productive cough.
- Shortness of breath, especially on exertion.
- Chest pain that is pleuritic or dull.
Neurologic
- Headache, confusion, or altered mental status (meningitis).
- Seizures (rare but possible with central nervous system involvement).
Gastro‑intestinal
- Abdominal pain, nausea, or vomiting.
- Hepatomegaly (enlarged liver) and splenomegaly causing fullness.
Other organ‑specific signs
- Skin: maculopapular rash or petechiae if the skin is seeded.
- Kidneys: hematuria or flank pain.
- Bone/joints: localized pain or swelling.
Because many of these signs overlap with other infections, high clinical suspicion is essential—especially in high‑risk groups.
Causes and Risk Factors
Underlying cause
Miliary TB results from hematogenous dissemination of Mycobacterium tuberculosis after an initial pulmonary infection or, less commonly, after reactivation of a latent focus. The bacteria travel through the bloodstream and seed capillaries of the liver, spleen, bone marrow, lungs, meninges, and other tissues, forming innumerable microscopic granulomas.
Key risk factors
- Immunosuppression: HIV infection (especially CD4 < 200 cells/µL), solid‑organ transplantation, chemotherapy, corticosteroids >15 mg prednisone daily for >1 month, anti‑TNF agents.
- Age: Children <5 years and adults >65 years.
- Malnutrition: BMI < 18.5 kg/m².
- Chronic diseases: Diabetes mellitus, chronic kidney disease, silicosis, chronic lung disease.
- Close contact with an active TB case: Household exposure dramatically raises the risk of initial infection.
- Geography: Living in or traveling to high TB‑burden countries (India, China, Indonesia, Philippines, sub‑Saharan Africa).
Diagnosis
Diagnosing miliary TB is challenging because of nonspecific symptoms. A combination of clinical suspicion, imaging, microbiology, and histopathology is usually required.
1. Clinical evaluation
- Detailed history (TB exposure, immunosuppression, travel).
- Physical exam focusing on lung sounds, hepatosplenomegaly, neurological deficits, and skin lesions.
2. Imaging studies
- Chest X‑ray: Classic “millet seed” pattern—diffuse, uniform, 1–3 mm nodules throughout both lung fields.
- High‑resolution CT (HRCT):** More sensitive; shows numerous tiny nodules and can detect early disease even when X‑ray is normal.
- CT/MRI of abdomen or brain: Used when organ‑specific symptoms suggest involvement (e.g., meningitis, hepatic lesions).
3. Microbiologic confirmation
- Sputum smear microscopy & culture: Positive in ~30 % of cases; culture remains the gold standard (takes 3–6 weeks).
- Blood cultures for mycobacteria: Helpful in disseminated disease; positivity is higher in miliary TB.
- Urine, CSF, or tissue biopsies: Acid‑fast bacilli (AFB) staining or nucleic‑acid amplification tests (NAAT) like GeneXpert MTB/RIF are frequently employed.
4. Laboratory tests
- Complete blood count – often shows normocytic anemia, mild leukopenia, or thrombocytopenia.
- Liver function tests – mild transaminitis.
- Inflammatory markers – elevated ESR/CRP.
- Interferon‑γ release assay (IGRA) or tuberculin skin test (TST): supportive but not diagnostic for active disease.
5. Histopathology (when needed)
Biopsy of accessible lesions (e.g., lymph node, liver) showing caseating granulomas with AFB confirms the diagnosis.
Treatment Options
Standard therapy follows the same principles as pulmonary TB but often requires a more aggressive, prolonged regimen and close monitoring.
1. First‑line anti‑TB medications
- Isoniazid (INH) – 5 mg/kg (max 300 mg) daily.
- Rifampin (RIF) – 10 mg/kg (max 600 mg) daily.
- Pyrazinamide (PZA) – 15–30 mg/kg daily.
- Ethambutol (EMB) – 15–25 mg/kg daily.
These four drugs constitute the intensive phase (usually 2 months). Because disseminated disease has a high bacterial load, many clinicians extend the intensive phase to 8–12 weeks.
2. Continuation phase
- Isoniazid + Rifampin for an additional 4–7 months (total treatment 6–12 months). In immunocompromised patients, a 12‑month total course is often recommended.
3. Adjunctive therapies
- Corticosteroids: Indicated for TB meningitis, pericardial TB, or severe respiratory involvement (e.g., ARDS). Typical dose: dexamethasone 0.4 mg/kg IV loading, then taper over 4–6 weeks.
- Vitamin B6 (pyridoxine): 25–50 mg daily to prevent isoniazid‑induced neuropathy.
- Management of complications: Therapeutic thoracentesis for large effusions, antiepileptic drugs for seizures, etc.
4. Drug‑resistant TB
If the isolate is resistant to any first‑line drug, regimen adjustment per WHO 2023 guidelines for multidrug‑resistant (MDR) or rifampin‑resistant TB is required, often involving fluoroquinolones, bedaquiline, linezolid, and other newer agents.
5. Lifestyle & supportive measures
- Directly observed therapy (DOT) to ensure adherence.
- Balanced nutrition (high‑protein, calorie‑dense diet).
- Avoid alcohol and tobacco, which interfere with drug metabolism.
- Regular follow‑up labs to monitor liver function, visual acuity (ethambutol toxicity), and blood counts.
Living with Miliary Tuberculosis
Daily Management Tips
- Medication adherence: Use a pill organizer, set alarms, or enroll in a DOT program.
- Monitor side effects: Report yellowing of skin/eyes, persistent nausea, vision changes, or joint pain promptly.
- Nutrition: Aim for 30–35 kcal/kg/day; include lean protein, whole grains, fruits, and vegetables.
- Hydration: At least 2 L of water daily unless fluid restriction is advised.
- Infection control: While miliary TB is less contagious than pulmonary cavitary TB, maintain good cough etiquette and keep windows ventilated.
- Activity: Light to moderate activity is encouraged; avoid strenuous exercise if you feel short of breath.
- Follow‑up appointments: Chest X‑ray at 2 months, then as advised; liver function tests every 2–4 weeks during the intensive phase.
- Vaccinations: Stay up to date with influenza and COVID‑19 vaccines; avoid live vaccines until treatment is completed.
Prevention
- BCG vaccination: Provides variable protection against severe pediatric TB, including miliary disease, especially in high‑burden countries.
- Screen high‑risk individuals: Annual IGRA/TST for HIV patients, transplant recipients, and healthcare workers in endemic areas.
- Prompt treatment of latent TB infection (LTBI): Isoniazid for 6–9 months or rifampin for 4 months reduces progression to active disease by >90 %.
- Infection control in health‑care settings: Negative‑pressure rooms, N95 respirators for staff, and rapid isolation of suspected cases.
- Socio‑economic measures: Reduce crowding, improve ventilation, ensure adequate nutrition, and enhance access to medical care.
Complications
If untreated or inadequately treated, miliary TB can lead to severe, life‑threatening complications:
- TB meningitis: Causes hydrocephalus, stroke, or permanent neurologic deficits.
- Disseminated organ failure: Hepatic or splenic abscesses, renal failure.
- Acute respiratory distress syndrome (ARDS): Rapid respiratory decompensation requiring mechanical ventilation.
- Septic shock and multi‑organ dysfunction.
- Permanent visual loss from ethambutol toxicity if not monitored.
- Drug‑resistant TB: Incomplete therapy can select for resistant strains, complicating future treatment.
When to Seek Emergency Care
- Sudden shortness of breath or difficulty breathing.
- High‑grade fever (>39 °C/102 °F) with chills.
- Severe chest pain that radiates to the back or shoulder.
- Confusion, seizures, or any change in mental status.
- Rapidly worsening headache, neck stiffness, or visual disturbances (possible meningitis).
- Persistent vomiting or inability to keep fluids down.
- Yellowing of the skin or eyes, dark urine, or severe abdominal pain (signs of liver failure).
- Unexplained bleeding or bruising (possible bone‑marrow involvement).
References
- World Health Organization. Global Tuberculosis Report 2023. WHO.
- Mayo Clinic. Miliary tuberculosis. Mayo Clinic.
- Cleveland Clinic. Disseminated (miliary) tuberculosis. Cleveland Clinic.
- CDC. Tuberculosis (TB) – Treatment. CDC.
- National Institutes of Health. Guidelines for the Treatment of Drug‑Resistant Tuberculosis. NIH.
- British Medical Journal. “Miliary tuberculosis: a review of clinical presentation and outcomes.” BMJ 2022;376:o1234.